Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia

American Journal of Surgical Pathology

Volumn 37, Issue 12, 2013, Pages 1815-1823

  Aron, Manju ^a   Luthringer, Daniel J ^a   Mckenney, Jesse K ^b   Hansel, Donna E ^b   Westfall, Danielle E ^a   Parakh, Rugvedita ^a   Mohanty, Sambit K ^a   Balzer, Bonnie ^a   Amin, Mahul B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

AMACR; bladder; carcinoma in situ; CD44s; CK20; p53; posttreatment changes; reactive atypia

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; CYTOKERATIN 20; DIAGNOSTIC AGENT; HERMES ANTIGEN; ISOMERASE; MONOCLONAL ANTIBODY; PROTEIN P53; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; CARCINOMA IN SITU; HUMAN; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; HUMANS; KERATIN-20; RACEMASES AND EPIMERASES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84888122738     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000114     Document Type: Article

References (34)

1. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435-1448
2. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer. 1999;85: 2469-2474
3. Nese N, Gupta R, Bui MH, et al. Carcinoma in situ of the urinary bladder: Review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Canc Netw. 2009;7:48-57
4. Shariat SF, Palpattu GS, Karakiewicz PI, et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007;51: 152-160
5. Palou J, Rodríguez-Rubio F, Millán F, et al. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology. 2009;73:1313-1317
6. McKenney JK, Gomez JA, Desai S, et al. Morphological expression of urothelial carcinoma in situ: A detailed evaluation of its histologic pattern with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001;25:356-362
7. Lopez-Beltran A, Luque RJ, Mazzucchelli R, et al. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol. 2002;55:641-647
8. Bassi P, Milani C, Meneghini A, et al. Clinical value of pathologic changes after intravesical BCG therapy of superficial bladder cancer. Urology. 1992 ;40:175-179
9. Oliva E, Kaufman DS, Shipley WU, et al. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder A study of 45 cases. Hum Pathol. 2013;44:860-866
10. Weiss C, Wittlinger M, Engehausen DG, et al. Management of superficial recurrences in an irradiated bladder after combinedmodality organ preserving therapy. Int J Radiat Oncol Biol Phys. 2008;70:1502-1506
11. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: Management and consequences of Ta, T1, and Yis recurrence within the retained bladder. Urology. 2001;58:380-385
12. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and nonneoplastic urothelium: An analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25:1074-1078
13. Sun W, Zhang PL, Herrera GA. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Appl Immunohistochem Mol Morphol. 2002;10:327-331
14. Yin H, He Q, Li T, et al. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol. 2006;14:260-265
15. Harnden P, Eardley I, Joyce AD, et al. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol. 1996;78:870-875
16. Retz M, Lehmann J, Amann E, et al. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J Urol. 2003; 169:86-89
17. Mallofré C, Castillo M, Morente V, et al. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16:187-191
18. Kunju LP, Lee CT, Montie J, et al. Utility of cytokeratin 20 and Ki- 67 as markers of urothelial dysplasia. Pathol Int. 2005;55:248-254
19. Yildiz IZ, Recavarren R, Armah H, et al. Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies. Diagn Pathol. 2009;4:35
20. Lima MV, Ferreira FV, Macedo FY, et al. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. Cancer Chemother Pharmacol. 2007;59: 643-650
21. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol. 1997;13:291-298
22. Hodges KB, Lopez-Beltran A, Davidson DD, et al. Urothelial dysplasia and other flat lesions of the urinary bladder: Clinicopathologic and molecular features. Hum Pathol. 2010;41:155-162
23. Cina SJ, Lancaster-Weiss KJ, Lecksell K, et al. Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Pathol Lab Med. 2001;125:646-651
24. Fujimoto K, Yamada Y, Okajima E, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res. 1992; 52:1393-1398
25. Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor Cd44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA. 1992;89:12160-12164
26. Goodison S, Urquidio V, Tarin D. CD44 adhesion molecules. Mol Pathol. 1999;52:189-196
27. Kuncova J, Urban M, Mandys V. Expression of CD44s and CD44v6 in transitional cell carcinoma of the urinary bladder: Comparison with tumor grade, proliferative activity and p53 immunoreactivity of tumor cells. APMIS. 2007;115:1194-1205
28. Ross JS, del Rosario AD, Bui HX, et al. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol. 1996;9:854-860
29. Stavropoulos NE, Filliadis I, Ioachim E, et al. CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors. Int Urol Nephrol. 2001;33:479-483
30. Zhou M, Chinnaiyan AM, Kleer CG, et al. Alpha-methylacyl-CoA racemase: A novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26: 926-931
31. Jiang Z, Fanger GR, Woda BA, et al. Expression of alpha-methylacyl- CoA racemase (P504s) in various malignant neoplasms and normal tissues: A study of 761 cases. Hum Pathol. 2003;34:792-796
32. Langner C, Rupar G, Leibl S, et al. Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch. 2006;448:325-330
33. Gunia S, May M, Scholmann K, et al. Expression of alphamethylacyl- CoA racemase correlates with histopathologic grading in non invasive bladder cancer. Virchows Arch. 2008;453:165-170
34. Amin MB, McKenney JK. An approach to the diagnosis of flat intraurothelial lesions of the urinary bladder using the World Health Organization/International Society of Urologic Pathology consensus classification system. Adv Anat Pathol. 2002;9:222-232